Researchers at Merck have identified targets in methicillin-resistant Staphylococcus aureus that synergize with beta-lactam antibiotic targets to restore antibiotic sensitivity. The findings suggest it may now be possible to use combinations of antibiotics to treat infections previously considered intractable.